Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 32 Records) |
| Query Trace: Fibrosis and JAK2[original query] |
|---|
| JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. Journal of clinical pathology 2009 Sep 62 (9): 798-801. Pich A, Riera L, Sismondi F, Godio L, Davico Bonino L, Marmont F, Francia di Celle |
| Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. British journal of haematology 2010 Apr 149 (2): 250-7. Boyd Elaine M, Bench Anthony J, Goday-Fernández Andrea, Anand Shubha, Vaghela Krishna J, Beer Phillip, Scott Mike A, Bareford David, Green Anthony R, Huntly Brian, Erber Wendy |
| The involvement of Galectins in the modulation of the JAK/STAT pathway in myeloproliferative neoplasia. American journal of blood research 2012 2 (2): 119-27. Koopmans Suzanne M, Bot Freek J, Schouten Harry C, Janssen Jannie, van Marion Arienne |
| JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis. PloS one 2013 8 (3): e59791. Barosi Giovanni, Poletto Valentina, Massa Margherita, Campanelli Rita, Villani Laura, Bonetti Elisa, Viarengo Gianluca, Catarsi Paolo, Klersy Catherine, Rosti Vittor |
| Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood 2013 May 121 (21): 4388-95. Rumi Elisa, Pietra Daniela, Guglielmelli Paola, Bordoni Roberta, Casetti Ilaria, Milanesi Chiara, Sant'Antonio Emanuela, Ferretti Virginia, Pancrazzi Alessandro, Rotunno Giada, Severgnini Marco, Pietrelli Alessandro, Astori Cesare, Fugazza Elena, Pascutto Cristiana, Boveri Emanuela, Passamonti Francesco, De Bellis Gianluca, Vannucchi Alessandro, Cazzola Mario, |
| Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2014 May 27 (5): 681-9. Fu Bin, Jaso Jesse M, Sargent Rachel L, Goswami Maitrayee, Verstovsek Srdan, Medeiros L Jeffrey, Wang Sa |
| Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms. Annals of clinical and laboratory science 2014 44 (2): 173-9. Ha Jung-Sook, Jeon Dong-Seok, Kim Jae-Ryong, Ryoo Nam-Hee, Suh Jang-S |
| Specifics of the course and the clinical pictures of essential thrombocythemia depending on the JAK2V617F status of the patients. Problemy radiatsiinoi medytsyny ta radiobiolohii 2015 Dec 20 399-413. Mishcheniuk O Y, Kostukevich O M, Dmytrenko I V, Klymenko S |
| Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Annals of hematology 2016 Jul . Pei Yu-Qing, Wu Yue, Wang Fei, Cui W |
| Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. Annals of hematology 2016 Dec . Lekovic Danijela, Gotic Mirjana, Skoda Radek, Beleslin-Cokic Bojana, Milic Natasa, Mitrovic-Ajtic Olivera, Nienhold Ronny, Sefer Dijana, Suboticki Tijana, Buac Marijana, Markovic Dragana, Diklic Milos, Cokic Vladan |
| Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 2016 12 129 (6): 680-692. Rumi Elisa, Cazzola Mar |
| Genetic Risk Assessment in Myeloproliferative Neoplasms. Mayo Clinic proceedings 2017 8 92 (8): 1283-1290. Tefferi Ayalew, Vannucchi Alessandro Mar |
| Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation. Journal of the National Comprehensive Cancer Network : JNCCN 2017 Jun 15 (6): 790-796. Hidalgo-López Juliana E, Kanagal-Shamanna Rashmi, Medeiros L Jeffrey, Estrov Zeev, Yin C Cameron, Verstovsek Srdan, Konoplev Sergej, Jorgensen Jeffrey L, Mohammad Mohammad M, Miranda Roberto N, Zhao Chong, Lee John, Zuo Zhuang, Bueso-Ramos Carlos |
| [The clinical characteristics, gene mutations and prognosis of chronic neutrophilic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2017 Jan 38 (1): 28-32. Cui Y J, Jiang Q, Liu J Q, Li B, Xu Z F, Qin T J, Zhang Y, Cai W Y, Zhang H L, Fang L W, Pan L J, Hu N B, Qu S Q, Xiao Z |
| The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. American journal of hematology 2017 Feb . Mudireddy Mythri, Barraco Daniela, Hanson Curtis A, Pardanani Animesh, Gangat Naseema, Tefferi Ayal |
| The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis. Journal of clinical pathology 2017 Dec . Kuo Ming-Chung, Lin Tung-Huei, Sun Chien-Feng, Lin Tung-Liang, Wu Jin-Hou, Wang Po-Nan, Huang Ying-Jung, Chang Hung, Huang Ting-Yu, Shih Lee-Yu |
| Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. Oncotarget 2017 Nov 8 (61): 103274-103282. Petrova-Drus Kseniya, Chiu April, Margolskee Elizabeth, Barouk-Fox Sharon, Geyer Julia, Dogan Ahmet, Orazi Attil |
| GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms. Annals of laboratory medicine 2018 Jul 38 (4): 296-305. Yang Naery, Park Sholhui, Cho Min Sun, Lee Miae, Hong Ki Sook, Mun Yeung Chul, Seong Chu Myong, Huh Hee Jin, Huh Jungw |
| Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. The American journal of surgical pathology 2018 Mar . Gur Hatice D, Loghavi Sanam, Garcia-Manero Guillermo, Routbort Mark, Kanagal-Shamanna Rashmi, Quesada Andres, Khogeer Haitham, Pierce Sherry, Medeiros L Jeffrey, Kantarjian Hagop, Khoury Joseph |
| Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis. Human pathology 2018 11 85 290-298. Hu Zhihong, Ramos Carlos E Bueso, Medeiros L Jeffrey, Zhao Chong, Yin C Cameron, Li Shaoying, Hu Shimin, Wang Wei, Thakral Beenu, Xu Jie, Verstovsek Srdan, Lin P |
| Mutation profile in Indian primary myelofibrosis patients and its clinical implications. South Asian journal of cancer 2019 9 8 (3): 186-188. Patil Vinod R, Chandrakala S, Mantri Shruti, Patil Rajesh, Wasekar Nilesh, Jijina Far |
| [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms]. Zhonghua nei ke za zhi 2019 12 59 (1): 35-39. Lyu X D, Li Y W, Guo Z, Xin Y P, Hu J Y, Fan R H, Song Y |
| Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms. Blood cells, molecules & diseases 2020 3 82 102420. Keski Hak |
| [Clinical impact of gene mutations on myeloproliferative neoplasms in Japan]. [Rinsho ketsueki] The Japanese journal of clinical hematology 2021 9 62 (8): 1060-1069. Morishita So |
| Portal vein thrombosis: A concise review (Review). Experimental and therapeutic medicine 2021 5 22 (1): 759. Costache Raluca S, Dragomiric? Andreea S, Dumitra? Elena A, Mariana Jinga, C?runtu Ana, Popescu Andrada, Costache Daniel |
| Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study. Frontiers in oncology 2021 4 11 637116. Cattaneo Daniele, Croci Giorgio Alberto, Bucelli Cristina, Tabano Silvia, Cannone Marta Giulia, Gaudioso Gabriella, Barbanti Maria Chiara, Barbullushi Kordelia, Bianchi Paola, Fermo Elisa, Fabris Sonia, Baldini Luca, Gianelli Umberto, Iurlo Alessand |
| Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms. Frontiers in oncology 2021 11 11 777730. Moia Riccardo, Cittone Micol Giulia, Boggione Paola, Manfredi Giulia Francesca, Favini Chiara, Awikeh Bassel, Pedrinelli Anita Rebecca, Mahmoud Abdurraouf Mokhtar, Nicolosi Maura, Bellan Mattia, Sainaghi Pier Paolo, Pirisi Mario, Gaidano Gianluca, Patriarca Andrea, Rigamonti Cristi |
| Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022 Jun . Tashakori Mehrnoosh, Khoury Joseph D, Routbort Mark J, Patel Keyur P, Wang Sa A, Ok Chi Young, El-Hussein Siba, Kanagal-Shamanna Rashmi, Luthra Rajyalakshmi, Hu Shimin, Lin Pei, Pemmaraju Naveen, Bose Prithviraj, Verstovsek Srdan, Bueso-Ramos Carlos E, Medeiros L Jeffrey, Loghavi San |
| Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels. Annals of hematology 2022 Oct . Lewandowski Krzysztof, Kandu?a Zuzanna, Gniot Micha?, Paczkowska Edyta, Nawrocka Paulina Maria, Wojtaszewska Marzena, Janowski Micha?, Mariak Magdalena, Handschuh Luiza, Kozlowski Pio |
| Molecular and Clinical Risk Factors Associated with Thrombosis and Bleeding in Myelofibrosis Patients. Hamostaseologie 2024 12 . Olga Morath, Carl Crodel, Jenny Rinke, Inken Sander, Aysun Tekbas, Manja Meggendorfer, Constance Baer, Andreas Hochhaus, Thomas Ern |
- Page last reviewed:Feb 1, 2024
- Content source: